Dopamine‐replacement therapy still stands as the most effective pharmacological strategy for the management of motor impairment associated with Parkinson’s disease. The present chapter aims to provide an overview of the pharmacology of dopamine‐replacement therapy in both preclinical experimental models of Parkinson’s disease and patients, and to present its light and shadows. The effect of dopamine‐replacement therapy on motor impairment, motor complications, non‐motor symptoms, and disease progression will be discussed, with a focus on future therapeutic directions.
Dopaminergic Treatments for Parkinson’s Disease: Light and Shadows
SIMOLA, NICOLA
2013-01-01
Abstract
Dopamine‐replacement therapy still stands as the most effective pharmacological strategy for the management of motor impairment associated with Parkinson’s disease. The present chapter aims to provide an overview of the pharmacology of dopamine‐replacement therapy in both preclinical experimental models of Parkinson’s disease and patients, and to present its light and shadows. The effect of dopamine‐replacement therapy on motor impairment, motor complications, non‐motor symptoms, and disease progression will be discussed, with a focus on future therapeutic directions.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Simola-RCS-Chapter 3-Complete.pdf
Solo gestori archivio
Tipologia:
versione post-print
Dimensione
461.38 kB
Formato
Adobe PDF
|
461.38 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
